Australia markets closed

Inovio Pharmaceuticals, Inc. (INO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
12.01+0.33 (+2.83%)
At close: 4:00PM EST

12.15 +0.14 (1.17%)
Pre-market: 4:53AM EST

Currency in USD

Valuation measures

Market cap (intra-day) 52.46B
Enterprise value 31.77B
Trailing P/E N/A
Forward P/E 1-19.69
PEG ratio (5-yr expected) 1N/A
Price/sales (ttm)1,164.22
Price/book (mrq)6.21
Enterprise value/revenue 3839.80
Enterprise value/EBITDA 6-14.84

Trading information

Stock price history

Beta (5Y monthly) 1.00
52-week change 3167.89%
S&P500 52-week change 323.92%
52-week high 333.79
52-week low 33.83
50-day moving average 311.83
200-day moving average 311.89

Share statistics

Avg vol (3-month) 316.08M
Avg vol (10-day) 314.43M
Shares outstanding 5204.55M
Float 166.76M
% held by insiders 12.17%
% held by institutions 136.49%
Shares short (11 Feb 2021) 443.09M
Short ratio (11 Feb 2021) 41.91
Short % of float (11 Feb 2021) 421.42%
Short % of shares outstanding (11 Feb 2021) 421.06%
Shares short (prior month 14 Jan 2021) 456.07M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:4
Last split date 305 Jun 2014

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2019
Most-recent quarter (mrq)29 Sep 2020


Profit margin 0.00%
Operating margin (ttm)-5,841.53%

Management effectiveness

Return on assets (ttm)-26.14%
Return on equity (ttm)-100.68%

Income statement

Revenue (ttm)2.11M
Revenue per share (ttm)0.01
Quarterly revenue growth (yoy)-72.80%
Gross profit (ttm)-82.01M
EBITDA -119.41M
Net income avi to common (ttm)-179.73M
Diluted EPS (ttm)-1.32
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)337.24M
Total cash per share (mrq)1.99
Total debt (mrq)74.62M
Total debt/equity (mrq)23.03
Current ratio (mrq)9.14
Book value per share (mrq)1.93

Cash flow statement

Operating cash flow (ttm)-140.5M
Levered free cash flow (ttm)-78.88M